Chronic kidney disease (CKD) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. RAAS inhibitors are cornerstones of CKD treatment. SGLT-2…
Age-related macular degeneration (AMD) is a degenerative and progressive ocular disease that diminishes central visual acuity as a result of photoreceptor degeneration in the macula. The wet AMD…
The market for multiple sclerosis (MS) disease-modifying therapies (DMTs) continues to fragment as newer entrants in established classes such as TG Therapeutics’ Briumvi, Novartis’s Kesimpta,…
The arrival of newer and more effective treatments in the U.S. psoriasis market is changing the treatment landscape and fueling competition for favorable coverage from MCOs. After years of…
In the United States, atypical antipsychotics available in oral and injectable (e.g., long-acting injectable [LAI]) formulations are the mainstay of schizophrenia treatment. However, the dearth of…
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically…
Dyslipidemia, characterized by abnormal lipid levels, plays a pivotal role in the development of cardiovascular (CV) disease. To address this risk factor, physicians use a range of lipid-modifying…
Eisai / Biogen’s Leqembi is set to capitalize on the unfulfilled potential for a disease-modifying therapy (DMT) for Alzheimer’s disease (AD), and additional anti-Aβ monoclonal antibodies (…
The age-related macular degeneration (AMD) therapy market in the United States is unique because the market penetration of approved branded therapies—Roche / Genentech’s Lucentis, Regeneron’s…
Sickle cell disease (SCD) is a rare genetic blood disorder characterized by polymerization of hemoglobin in red blood cells that distorts them into a sickle shape, leading to various complications…
The psoriatic arthritis (PsA) therapy market has become increasingly dynamic with the recent launches of several targeted agents—AbbVie’s Rinvoq and Skyrizi and UCB’s bimekizumab. Furthermore…
Vaccination programs have had a revolutionary impact on global public health, not only leading to dramatic reductions in the incidence of infectious diseases but also reducing childhood and adult…
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the location of the obstruction…
The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen / Pfizer’s Enbrel, AbbVie’s Humira,…
The type 2 diabetes (T2D) therapy market is forecast to expand through 2032, supported by polypharmacy and growing use of later-line therapies; however, loss of exclusivity for several key T2D…